- $238.29bn
- $264.84bn
- $45.81bn
- 93
- 26
- 70
- 66
REG - AstraZeneca PLC - AstraZeneca licenses lipid lowering Lp(a) asset
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Tagrisso US approval in unresectable lung cancer
AnnouncementREG - AstraZeneca PLC - Fasenra recommended for EU approval in EGPA
AnnouncementREG - AstraZeneca PLC - Final OS results reported for TROPION-Breast01
AnnouncementREG - AstraZeneca PLC - FluMist approved for self-administration in US
AnnouncementREG - AstraZeneca PLC - Fasenra EGPA US FDA approval
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in US for resectable lung cancer
AnnouncementREG - Societe Generale SA - Post-Stabilisation Notice- Astrazeneca
AnnouncementREG - Stock Exch Notice - Admission to Trading - 05/08/2024
AnnouncementREG - Official List - Official List Notice
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - AstraZeneca prices a €1.4bn bond offering
AnnouncementREG - Societe Generale SA - Stabilisation Notice - ASTRAZENECA
AnnouncementREG - Societe Generale SA AstraZeneca PLC - Stabilisation Notice - ASTRAZENECA
AnnouncementREG - AstraZeneca PLC - Calquence fixed-duration combo improved 1L CLL PFS
AnnouncementREG - AstraZeneca PLC - ODAC reviewed Imfinzi in resectable lung cancer
Announcement